SCMP Sucampo Pharmaceuticals, Inc.

10.75
-0.10  -1%
Previous Close 10.85
Open 10.85
Price To book 2.71
Market Cap 499.49M
Shares 46,464,000
Volume 351,598
Short Ratio 11.42
Av. Daily Volume 544,933

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved April 23, 2013.
Amitiza/Lubiprostone
Opioid-induced bowel dysfunction
Cobiprostone development discontinued July 2016
Cobiprostone
Oral Mucositis
Phase 3 endpoint not met. Phase 3 trials to be initiated in mid 2017.
Lubiprostone
Pediatric functional constipation
Phase 2a trial did not meet endpoints
Cobiprostone
proton pump inhibitor (PPI)-refractory non-erosive reflux disease (NERD) or symptomatic gastroesophageal reflux disease (sGERD)

Latest News

  1. Sucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCMP-US : June 22, 2017
  2. ETFs with exposure to Sucampo Pharmaceuticals, Inc. : June 19, 2017
  3. Sucampo Pharmaceuticals, Inc. :SCMP-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017
  4. 3 Hiddem Gems in the Healthcare Sector
  5. Sucampo Pharmaceuticals Announces Issuance of New Patent for VTS-270
  6. Why Is Sucampo (SCMP) Up 1.5% Since the Last Earnings Report?
  7. Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Jefferies 2017 Global Healthcare Conference
  8. Sucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCMP-US : May 29, 2017
  9. Edited Transcript of SCMP earnings conference call or presentation 3-May-17 12:30pm GMT
  10. Cerecor Appoints Steven Boyd and Peter Greenleaf to Board of Directors
  11. Sucampo Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SCMP) : May 12, 2017
  12. Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Bank of America Merrill Lynch 2017 Health Care Conference
  13. Sucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCMP-US : May 11, 2017
  14. Investor Network: Sucampo Pharmaceuticals, Inc. to Host Earnings Call
  15. Sucampo tops 1Q revenue forecasts
  16. Sucampo Reports First Quarter 2017 Financial Results
  17. Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Deutsche Bank 42nd Annual Health Care Conference
  18. ETFs with exposure to Sucampo Pharmaceuticals, Inc. : April 26, 2017
  19. Sucampo Announces First Quarter 2017 Earnings Call
  20. New Study Published in PLOS ONE Advances Science Around VTS-270 for Treatment of Niemann-Pick Disease Type C1